tbuckley/cabot-search huggingface dataset:
Scarlet Fever Spread by Ice.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chronic pancreatitis
Authors: Pramod Kumar Garg
Journal: Gut (2012)

<h3>Abstract</h3> A few genes have previously been identified in which very rare variants can have major effects on lipid levels. Weighted burden analysis of rare variants was applied to 200,000 exome sequenced UK Biobank subjects with hyperlipidaemia as the phenotype, with the strength of association characterised by the signed log 10 p value (SLP). With principal components included as covariates there was a tendency for genes on the X chromosome to produce strongly negative SLPs, and this was found to be due to the fact that rare X chromosome variants were identified less frequently in males than females. The test performed well when both principal components and sex were included as covariates and strongly implicated <i>LDLR</i> (SLP = 50.08) and <i>PCSK9</i> (SLP = −10.42) while also highlighting other genes previously found to be associated with lipid levels. Category-specific analyses of variants in these two genes revealed that, while there were loss of function variants with major effects, there were much larger numbers of protein-altering variants which had moderate effects on risk of hyperlipidaemia. Variants classified by SIFT as deleterious have on average a two-fold effect and their cumulative frequency is such that they are present in approximately 1.5% of the population. There was no evidence for association of <i>HUWE1</i>, which had produced statistically significant results in an earlier analysis of a subset of 50,000 exomes, and with hindsight this result had been caused by the excess of X gene variants in females. These analyses shed further light on the way that genetic variation contributes to risk of hyperlipidaemia and in particular that there are very many protein-altering variants which have on average moderate effects and whose effects can be detected when large samples of exome-sequenced subjects are available.
Fourteenth Congress of the Pan-Pacific Surgical Association
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Fourteenth Congress of the Pan-Pacific Surgical Association Get access JNCI: Journal of the National Cancer Institute, Volume 57, Issue 5, November 1976, Page 1203, https://doi.org/10.1093/jnci/57.5.1203 Published: 01 November 1976
Femoral Nerve Conduction
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SEPTICEMIA.
Authors: CHARLES PERN ROBBINS
Journal: JAMA (1897)

A few years past no one would have listened to the assertion that a relation exists between lower organisms and certain forms of disease. The secretions were admitted to contain some elements of a physicochemic character, irritative in nature and capable of producing pathologic processes. A large class of miasmatic and contagious diseases are not only admitted by the most eminent pathologists and bacteriologists of today, but are referred by them direct to the animal and vegetable parasites. Evidence is positive proof that septicemia should be mentioned in this connection. What can be clearer since Saunderson's and Bert's investigations in 1873 of the relation between intensity of septicemia and pyemia depends upon microorganisms? I desire to present to you an original research of septicemia on guinea pigs, rabbits, mice, dogs and sparrows which were carried out in the private laboratory of DaCosta and Kyle, Philadelphia, later on continued in the
Editors' response
Authors: A. Bush, I. Pavord
Journal: Thorax (2010)

bronchodilator-containing inhalers and placebo inhalers in a clinical trial setting.We are puzzled to be criticised for reference to older literature on electronic adherence devices 9 and sought only to point out that electronic monitoring of relevant dry powder inhalers had long been available to explore the hypothesis that timing of medication use was somehow important to the mechanism of action of SMART.Reddel and Yan have mentioned numerous 'errors' in our review but provided only examples of our emphasis on control and compliance assessments hitherto overlooked in SMART research; we look forward to correcting any errors of fact they detect and report to us.Finally, we wish to clarify further our thoughts concerning the measurement of inflammatory indices in SMART-treated patients.We agree with Peters and Jenkins that control outcomes were neither superior nor inferior for SMART compared with fixed dose treatment in the study by Pavord and colleagues, 10 and would add that the study was neither adequately powered nor designed to examine this outcome.With respect to eosinophil counts being 'in the range of control', we are not sure that there is sufficient long-term literature using sputum eosinophil counts to declare with confidence that a particular level of airway eosinophilia is safe and acceptable in asthma.However, if one accepts that levels of <3% are tolerable, we note that it was only the mean sputum eosinophil count that was within this limit for SMART-treated patients and the rise in sputum eosinophils seen with SMART therapy probably increased the proportion of SMART-treated patients above the 'acceptable' limit.We find this increase as well as the doubling of biopsy eosinophil counts concerning.
GRADUATE TRAINING IN NERVOUS AND MENTAL DISEASES
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Why has 'historic' public disclosure of hospital performance data attracted so little attention?
Authors: R. Voelker
Journal: JAMA (1995)

CONSUMERS, COMPETITORS, and payers aren't exactly rushing to snap up the first national reports on hospital performance. "After a huge amount of hullabaloo nationally, this has become a great nonevent," says Dennis S. O'Leary, MD, president of the Joint Commission on Accreditation of Healthcare Organizations. Two years ago, when the Joint Commission announced plans to permit public access to some of the information it compiles during the accreditation process, the move was called historic. But during the first 6 weeks that the reports became available, 97 callers placed orders for 167 of the performance profiles. "This is bearing out my expectations," O'Leary adds. <h3>Measuring Hospital Performance</h3> The Joint Commission accredits more than 5200 hospitals and 6000 other health care organizations nationwide. Performance reports currently are available for only about 850 hospitals because they're produced according to the Commission's 3-year accreditation cycle. Reports for all Joint Commission—accredited facilities will be completed
Addiction to aerosol treatment.
Journal: BMJ (1983)

risk of giving double the usual starting dose of a new agent in conjunction with the underlying benorylate should have been considered potentially dangerous.That these patients were both in their 70s should have invited particular care.Regardless of the attributes, or otherwise, of Osmosin or any new anti-inflammatory agent, it is unfortunate that a new drug should fall into disrepute as a result of inadequate attention to dosage, unwarranted polypharmacy, or lack of concern for the patient's age.
Correction: The cholesterol controversy
Authors: Mayer Hillman
Journal: BMJ (1992)

feasible, it could be judged irresponsible not to do so owing to the risk to health of not getting regular exercise.Given proper provision for it, for the great majority of the population cycling as part of the routine of daily travel has the potential for improving fitness in a way that cannot be matched by any other comparable exercise regime-for instance, the report shows that there is only one public swimming bath for every 45 000 people in Britain.
Morphologic Constitution and Smoking
Authors: Carl C. Seltzer
Journal: JAMA (1963)

A study of 922 college men was made relating their morphological characteristics as students to their subsequent histories of smoking 13 yr after graduation, in order to ascertain the extent to which the different classes of nonsmokers, cigarette smokers, pipe smokers, and cigar smokers were phenotypically and genotypically conditioned. Significant differences in physique were found between smokers and nonsmokers and in accordance with the form of smoking adopted. Smokers were consistently greater than nonsmokers in height and weight and in the dimensions of the head, face, shoulders, chest, hip, leg, and hand. The findings delineate constitutional differences between smokers and nonsmokers and among the several varieties of smokers. Smoking behavior thus appears to be in part a reflection of the biological or genetic make-up of the individual.
Ophthalmology
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hypertension, Body Weight, and Coronary Heart Disease
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Münchencer Medizinische Wochenschrift
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vitamin abuse
Authors: S. Vaisrub
Journal: JAMA (1977)

When Casimir Funk introduced the term "vitamine" in 1913 (later to be changed to "vitamin"), he may have made an unfortunate choice.<i>Vita</i>, Latin for life, has a charismatic sound. It suggests vitality, élan vital, a vital force. To this charisma can in part be attributed the popularity of vitamins, which are consumed in excessive amounts not only when they may be of some benefit, but also when they are utterly useless. Massive doses of vitamin A for osteoarthritis and neuropsychiatric disorders, of vitamin D for osteoporosis, of vitamin C for prevention of colds and influenza, of vitamin B1 for "neuritis", of vitamin E for sterility and coronary heart disease, and of the pseudovitamin B<sub>17</sub>(laetrile) for cancer are all conspicuous examples of vitamin therapy misuse. It may be argued, of course, that misuse is not necessarily abuse. It may be said that megavitamin therapy is a reassuring placebo,
High-density lipoprotein-cholesterol in survivors of myocardial infarction
Authors: D. W. Erkelens
Journal: JAMA (1979)

High-density lipoprotein-cholesterol (HDL-Chol) levels were higher in a group of 83 myocardial infarction survivors who participated in a moderate, graded exercise program (47±13 mg/dL) than in 103 nonexercising coronary heart disease patients (40±11 mg/dL,<i>P</i>&lt;.001), reaching levels undistinguishable from those of 181 population controls (44±12 mg/dL). The level of exercise and concentration of HDL-Chol were correlated (<i>r</i>=.24,<i>P</i>&lt;.05). In 18 patients studied longitudinally, HDL-Chol levels increased from 35±8 mg/dL before participation to 40 mg/dL (<i>P</i>&lt;.001) after one week, and remained at that level for six months. Concurrently, functional aerobic impairment decreased from 31%±29% to 11% (<i>P</i>&lt;.01). These observations suggest that participation in a moderate exercise program increases HDLChol levels in myocardial infarction survivors and may contribute to lowering the risk for subsequent infarction. (<i>JAMA</i>242:2185-2189, 1979)
Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population.
Authors: H. Khambati, T. K. Choueiri, C. K. Kollmannsberger, S. North, G. A. Bjarnason, U. N. Vaishampayan, L. Wood, M. J. MacKenzie, B. I. Rini, D. Y. Heng
Journal: Journal of Clinical Oncology (2011)

318 Background: Targeted therapy has become the mainstay of treatment for metastatic renal cell carcinoma (mRCC). The efficacy of this therapy on the older population is poorly understood. Methods: Data from patients with mRCC treated with first-line anti-VEGF therapy were collected through the International mRCC Database Consortium from 14 centers. Results: One thousand three hundred eighty-one patients were treated with targeted therapy as their first-line treatment. Of those, 144 (10%) were seventy-five years or older (median=78 years, range=75–89). Four percent of these individuals were favorable risk, 69% intermediate risk, and 27% poor risk as per Heng et al. JCO 2009 prognostic factors. There was no statistical difference in these prognostic groups between the older (≥75) and younger populations (&lt;75) (p=0.1779). The initial treatment for those ≥ 75 years was with sunitinib (n=98), sorafenib (n=35), bevacizumab (n=7), and AZD2171 (n=4). The older population had fewer nephrectomies (71% vs. 80%, p=0.0133) and fewer brain metastases (3% vs. 9%, p=0.0128). Only 23% of older patients went on to receive second line therapy in comparison to 39% of the younger population (p&lt;0.0001). The overall response rate, median treatment duration and overall survival for the older vs. younger group were 18% vs. 25% (p=0.0975), 5.5 months vs. 7.5 months (p=0.1388), and 16.8 months vs. 19.7 months (p=0.3321), respectively. When adjusted for known poor prognostic factors, age over 75 years was not found to be associated with poorer overall survival (HR 1.002, 95%CI 0.781–1.285) or shorter treatment duration (HR 1.018, 95%CI 0.827–1.252). Conclusions: Overall response rates, treatment duration, and overall survival rates are not different between the older and younger populations and age is not a prognostic factor. Thus, the decision to treat with targeted therapy should not depend on age alone. [Table: see text]
Archives of Pathology, Chicago
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Headaches
Authors: Dhirendra S. Bana
Journal: JAMA (1994)

In an information age, comprehensive information is precisely what you get in<i>The Headaches</i>. This multiauthored book skillfully draws upon the international community to derive its broad base of authoritative knowledge. By design, most of the chapters are coauthored by specialists from different centers, which in many cases also span different continents. In our continuous search to understand and treat the problem of headaches, this book truly brings the investigations and analysis to an exciting new level. Starting with a historical background of headaches, the first section attributes the initial migraine headache description to Aretaios of Kappadokia in the first century AD. From there the author traces the documentation of headaches through the Middle Ages, the Renaissance, and finally into the 20th century through the current classic text<i>Headaches and Other Head Pain</i>, by H. G. Wolff. Background information is subsequently followed by part 2's discussions of applied anatomy, physiology,
Cecal mass
Authors: D. Nolan
Journal: JAMA (1977)

<h3>History</h3> A 46-year-old woman was first examined 14 years ago for a history of bloody diarrhea. A diagnosis of ulcerative colitis was made. The disease had been in remission for most of the time since then. It recurred in July 1974, when she again had multiple loose stools containing blood. She also complained of a dull ache in the right iliac fossa. On examination, a small, vague, slightly tender mass was palpable there. A plain film on the abdomen showed no abnormality. Figures 1 and 2 were made during barium enema examination. <h3>Diagnosis</h3> Mucocele of the appendix. <h3>Comment</h3> The characteristic roentgenographic appearance of a round, welldefined filling defect in the cecum with nonfilling of the appendix enabled the correct preoperative diagnosis to be made. The small, round, translucent area about 4 mm in diameter visible in the center of the larger mass represented the proximal end of the appendix, which